RVNC Revance Therapeutics Inc.

15.93
-0.68  -4%
Previous Close 16.61
Open 16.81
Price To Book 4.75
Market Cap 718,576,175
Shares 45,108,360
Volume 2,105,928
Short Ratio
Av. Daily Volume 533,321
Stock charts supplied by TradingView

NewsSee all news

  1. Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

    DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in

  2. Revance Announces Pricing of Public Offering of Common Stock

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the

  3. Revance Announces Proposed Public Offering of Common Stock

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a

  4. Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

    - Appointment completes build-out of Revance's commercial leadership team following submission of the Company's Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for

  5. Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2H 2020.
DAXI (RT002)
Plantar fasciitis
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Lateral Canthal (Crow’s Feet) Lines
Phase 3 data due 2H 2020.
DAXI (RT002) - ASPEN
Cervical dystonia
BLA submission announced November 25, 2019.
DAXI (RT002)
Moderate to severe glabellar (frown) lines
Phase 2 trial to be initiated in 2020.
DAXI (RT002)
Chronic migraine
Phase 2 completion of enrolment due 1H 2020.
DAXI (RT002)
Upper limb spasticity
Phase 2 top-line data due 1H 2020.
DAXI (RT002)
Forehead lines

Latest News

  1. Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

    DaxibotulinumtoxinA for Injection (DAXI) demonstrated prolonged duration of response for glabellar line reduction Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in

  2. Revance Announces Pricing of Public Offering of Common Stock

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the

  3. Revance Announces Proposed Public Offering of Common Stock

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a

  4. Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

    - Appointment completes build-out of Revance's commercial leadership team following submission of the Company's Biologics License Application to the U.S. Food and Drug Administration for DaxibotulinumtoxinA for

  5. Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics

  6. Revance to Participate in the Stifel 2019 Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel

  7. Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update

    – Conference call and webcast today at 4:30 p.m. ET – Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today

  8. Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia

    - DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder - - Topline data expected in second half of 2020

  9. Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery

    - Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new

  10. Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019

    Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic

  11. Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

    - Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of

  12. Revance Earns Great Place to Work® Certification for Second Year

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by

  13. Revance to Participate in the 2019 Cantor Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019

  14. Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan

  15. Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference

    Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells